April 2008 Oncology News International

Axicabtagene ciloleucel may prolong survival and improve outcomes vs standard-of-care therapy in older patients with relapsed/refractory large B-cell lymphoma.

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Luspatercept may lead to a paradigm shift in the treatment of patients with lower-risk myelodysplastic syndrome, according to an expert from The University of Texas MD Anderson Cancer Center.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

A positive R0 resection rate helped to confirm the noninferiority of minimally invasive distal pancreatectomy compared with open distal pancreatectomy in those with resectable pancreatic cancer.

18F-Fluorestradiol is currently the only imaging agent approved by the FDA for assessing estrogen receptor–positive lesion status to better guide treatment decision-making.